CMA
KRYS icon

Cedar Mountain Advisors’s Krystal Biotech KRYS Stock Holding History

Cedar Mountain Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11K Hold
3
– – ﹤0.01% 932
2026
Q1 		$775 Buy
+3
New +$798 ﹤0.01% 957

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cedar Mountain Advisors's KRYS Position: Q2 2026 in Review

Cedar Mountain Advisors held its Krystal Biotech (KRYS) position steady in Q2 2026 at 3 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

Cedar Mountain Advisors first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cedar Mountain Advisors held 3 shares of Krystal Biotech worth $1.11K as of Q2 2026.
  • Cedar Mountain Advisors left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #932 holding.
  • Cedar Mountain Advisors first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.